Financing ·
BioVie raises $4.74M in registered direct offering of common stock and warrants
BIVIBiovie Inc.
BioVie Inc. closed a registered direct offering on November 5, 2026, raising approximately $4.74 million in gross proceeds before fees. The company issued 960,000 shares of Class A common stock at $1.60 per share and 2,002,500 pre-funded warrants at $1.5999 each to an institutional investor. Concurrently, it sold 2,962,500 common warrants with a $1.70 exercise price in a private placement. Net proceeds will support working capital and general corporate purposes. BioVie is a clinical-stage biopharmaceutical company developing therapies for neurological disorders and advanced liver disease.